Graham Capital Management’s ADMA Biologics ADMA Stock Holding History

Graham Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-45,222	Closed	-$407K	–	1229
2026 Q1	$407K	Buy	+45,222	New	+$714K	0.01%	699
2025 Q1	–	Sell	-11,726	Closed	-$201K	–	1263
2024 Q4	$201K	Buy	+11,726	New	+$221K	﹤0.01%	1080
2024 Q3	–	Sell	-13,544	Closed	-$151K	–	1071
2024 Q2	$151K	Sell	13,544 -17,730	-57%	-$149K	﹤0.01%	895
2024 Q1	$206K	Sell	31,274 -6,361	-17%	-$34.8K	﹤0.01%	890
2023 Q4	$170K	Buy	37,635 +9,430	+33%	+$34.9K	﹤0.01%	861
2023 Q3	$101K	Sell	28,205 -10,727	-28%	-$41.3K	﹤0.01%	937
2023 Q2	$144K	Buy	+38,932	New	+$144K	﹤0.01%	861
2022 Q2	–	Sell	-185,654	Closed	-$339K	–	978
2022 Q1	$339K	Buy	+185,654	New	+$290K	0.01%	697

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Graham Capital Management's ADMA Position: Q2 2026 in Review

Graham Capital Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 45,222 shares — an estimated $407K sold.

Graham Capital Management first reported a position in ADMA in Q1 2022 and held it in 8 quarters. The position peaked at $407K in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Graham Capital Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
Graham Capital Management sold 45,222 ADMA Biologics shares in Q2 2026, an estimated $407K.
Graham Capital Management first reported a position in ADMA Biologics in Q1 2022 and held it in 8 quarters.
Graham Capital Management's ADMA Biologics position peaked at $407K in Q1 2026.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.